Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing.
Stefanie K MenziesThea Litschka-KoenRebecca J EdgeJaffer AlsolaissEdouard CrittendenSteven R HallAdam WesthorpeBrent ThomasJames MurrayNondusimo ShongweSara PadidarDavid G LallooNicholas R CasewellJonathan PonsRobert A HarrisonPublished in: PLoS neglected tropical diseases (2022)
While both Panafrican and PANAF antivenoms exhibited promising preclinical efficacies, both were less poly-specifically effective than SAIMR Polyvalent in these murine assays. The efficacy of these antivenoms against the lethal and tissue-destructive effects of N. mossambica venom, the most common biting species in Eswatini, identify that Panafrican and PANAF antivenoms offer effective alternatives to SAIMR Polyvalent for the treatment of snakebite in Eswatini, and potentially for neighbouring countries.